research Cells, Growth Factors and Biomaterials Used in Tissue Engineering for Hair Follicles Regeneration
Advancements in tissue engineering show promise for hair follicle regeneration to treat hair loss.
Search
for
Sort by
Research
390-420 / 1000+ resultsresearch The Molecular Mechanism of Natural Products Activating Wnt/Beta-Catenin Signaling Pathway for Improving Hair Loss
Natural products may help treat hair loss by promoting hair growth with fewer side effects.
research Selective Inhibition of Tyrosine Kinase 2 Prevents and Restores Interleukin-12-Induced Hair Follicle Immune Privilege Collapse: A Novel Approach to Alopecia Areata Therapy?
Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.
research Tyrosine Kinase Inhibitors: A Review on Pharmacology, Metabolism, and Side Effects
Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
research Hair Graying and Loss Induced by Imatinib Mesylate
A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.
research Drug Repurposing Patent Applications April–June 2021
Drug repurposing shows promise for treating many medical conditions.
research A Case of Inflammatory Nonscarring Alopecia Associated With the Tyrosine Kinase Inhibitor Nilotinib
A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.
research Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.
research Adverse Cutaneous Reactions to the New Second-Generation Tyrosine Kinase Inhibitors (Dasatinib, Nilotinib) in Chronic Myeloid Leukemia
Many patients on new leukemia drugs had mild to moderate skin reactions.
research Tyrosine Kinase 2 Inhibition Ameliorates the Phenotype of Lesional Alopecia Areata Scalp Skin Ex Vivo, and Reverses the Induction of Human Alopecia Areata in a Humanized Mouse Model
TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.
research Tyrosine Kinase 2 Inhibition Rescues Hair Follicles From IL-12-Mediated Immune Privilege Collapse And Reverses Human Alopecia Areata In A Humanized Mouse Model
Inhibiting TYK2 can restore hair growth in alopecia areata.
research Keratosis Pilaris-Like Eruption During Chronic Myeloid Leukemia Treatment With Tyrosine Kinase Inhibitors: A Literature Review And Case Report On Imatinib
Some leukemia treatments can cause skin reactions similar to keratosis pilaris.
research Inhibition of a Signaling Modality Within the Gp130 Receptor Enhances Tissue Regeneration and Mitigates Osteoarthritis
Blocking a certain signal in the gp130 receptor can improve tissue healing and lessen osteoarthritis symptoms.
research Mechanisms of Hepatocyte Attachment to Keratin Biomaterials
Human liver cells stick to hair protein materials mainly through the liver's asialoglycoprotein receptor.
research Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia
A woman's hair turned white after taking a cancer drug called dasatinib.
research Are All Adverse Effects Undesirable? A Case of Chemotherapy-Induced Adverse Effect - An Exception!
Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
research Activity of Sorafenib Against Desmoid Tumor/Deep Fibromatosis
Sorafenib is effective in treating Desmoid Tumor/Deep Fibromatosis.
research Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-Small Cell Lung Cancer
A cancer patient's eyelashes grew excessively without other common side effects after taking the cancer drug erlotinib.
research Dermal Fibroblasts Enhance Growth Factors Production by Androgens and Modulate Keratinocyte Proliferation and Differentiation
Androgens increase growth factors in skin cells, which may lead to acne.
research What's New in Dermatological Research?
2011 dermatological research found new skin aging markers, hair loss causes, skin defense mechanisms, and potential for new treatments.
research Synthesis, Anticancer, and Molecular Docking Studies of 2-(4-Chlorophenyl)-5-Aryl-1,3,4-Oxadiazole Analogues
The compound 4c showed strong potential as an anticancer agent.
research Unexpected Autocrine Role of Vascular Endothelial Growth Factor in Squamous Cell Carcinoma
VEGF helps squamous cell carcinoma grow in ways beyond just blood vessel formation.
research Erosive Pustular Dermatosis of the Scalp Induced by Gefitinib: Case and Review of the Literature
An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.
research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
research Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
research A Novel Approach to Manage Skin Toxicity Caused by Therapeutic Agents Targeting Epidermal Growth Factor Receptor
New treatment with green tea polyphenols and nicotinamide improves skin problems from cancer therapy.
research Targeting the Janus Kinase Family in Autoimmune Skin Diseases
Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
research Perifollicular Xanthomas Associated With Epidermal Growth Factor Receptor Inhibitor Therapy
EGFR inhibitors can cause yellowish skin eruptions.
research Antisense Oligonucleotide Targeting Fibroblast Growth Factor Receptor-1 Stimulates Cellular Activity of Hair Follicles in an In Vitro Organ Culture System
Targeting FGFR-1 with antisense oligonucleotides may help treat baldness by increasing hair follicle activity.
research Safety of Janus Kinase Inhibitors in Patients with Alopecia Areata: A Systematic Review
JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.